Last edition
News about "UNLOXCYT"
Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.
UNLOXCYT | 16/01/2026 | By News Bureau | 114
US FDA Approves Label Update for Sun Pharma's UNLOXCYT
Sun Pharma has received US FDA approval for a label update to UNLOXCYT, the first and only PD-L1 inhibitor for advanced Cutaneous Squamous Cell Carcinoma (aCSCC), further supporting its clinical value with durable responses and a favourable safety profile for patients with multiple comorbidities.
UNLOXCYT | 27/11/2025 | By Dineshwori | 168
Sun Pharma to Acquire Checkpoint Therapeutics
Checkpoint has received approval from the US Food & Drug Administration (FDA) for UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation.
UNLOXCYT | 10/03/2025 | By Aishwarya | 213
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy